Overview
Practical Approaches to Diagnosis and Treatment of CF-ILD
CF-ILD Flipbook
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This web-based multi-faceted digital flipbook addresses the latest diagnostic and treatment strategies for patients with CF-ILD. To improve knowledge retention and recall, text-based education is enhanced through video and audio snippets from a leading pulmonology expert, on how to optimize diagnosis, treatment, monitoring, and multidisciplinary collaboration. Videos, charts, and sound bytes will be interspersed throughout the chapters to aid learning and discussion on difficult real-world patient cases as well as the definition and differentiation of CF-ILDs, CF-ILD pharmacotherapies, and supportive care.
This activity is intended for community pulmonologists, pulmonologists, rheumatologists, and other healthcare clinicians (MD’s, PAs, and NPs) interested in treating patients with chronic fibrosing interstitial lung disease (ILD).
Clinicians have demonstrated a lack of understanding of identifying patients at risk for or with chronic fibrosing interstitial lung disease (CF-ILD), an umbrella term for multiple respiratory conditions associated with poor prognosis and limited treatment options. In addition, clinicians require education on CF-ILD pharmacologic and nonpharmacologic therapy. Clinicians need to also better understand the necessity and role of interdisciplinary collaboration when monitoring and managing CF-ILD. This activity will help learners overcome all of these aforementioned gaps to better ensure that their patients with CF-ILD receive appropriate care achieve optimal outcomes.
Upon completion of this activity, participants will be able to:
• Identify patients with CF-ILD based on clinical, radiologic, and other features
• Outline the steps of a comprehensive evaluation to ensure a diagnosis of CF-ILD
• Evaluate pharmacologic and nonpharmacologic approaches to managing CF-ILD
• Discuss the role of multidisciplinary collaboration in monitoring and managing CF-ILD
• Identify patients with CF-ILD based on clinical, radiologic, and other features
• Outline the steps of a comprehensive evaluation to ensure a diagnosis of CF-ILD
• Evaluate pharmacologic and nonpharmacologic approaches to managing CF-ILD
• Discuss the role of multidisciplinary collaboration in monitoring and managing CF-ILD
Sponsored by the Academy for Continued Healthcare Learning
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Imre Noth, MD
Chief of Pulmonary & Critical Care Medicine
Professor of Medicine
University of Virginia School of Medicine
Charlottesville, Virginia
Chief of Pulmonary & Critical Care Medicine
Professor of Medicine
University of Virginia School of Medicine
Charlottesville, Virginia
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Imre Noth, MD
Consultant: Boehringer Ingelheim and Genentech
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Agents under investigation for ILD.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
